
Jonathan Himmelfarb

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3984941/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Participant-Centered Approach to Understanding Risks and Benefits of Participation in Research Informed by the Kidney Precision Medicine Project. American Journal of Kidney Diseases, 2022, 80, 132-138.	1.9	3
2	Angiopoietins as Prognostic Markers for Future Kidney Disease and Heart Failure Events after Acute Kidney Injury. Journal of the American Society of Nephrology: JASN, 2022, 33, 613-627.	6.1	16
3	Serum Protein Exposure Activates a Core Regulatory Program Driving Human Proximal Tubule Injury. Journal of the American Society of Nephrology: JASN, 2022, 33, 949-965.	6.1	10
4	Strategies for optimizing urea removal to enable portable kidney dialysis: A reappraisal. Artificial Organs, 2022, 46, 997-1011.	1.9	5
5	A reference tissue atlas for the human kidney. Science Advances, 2022, 8, .	10.3	67
6	A prospective cohort study of acute kidney injury and kidney outcomes, cardiovascularÂevents, and death. Kidney International, 2021, 99, 456-465.	5.2	72
7	Prediction of Kidney Drug Clearance: A Comparison of Tubular Secretory Clearance and Glomerular Filtration Rate. Journal of the American Society of Nephrology: JASN, 2021, 32, 459-468.	6.1	15
8	Rationale and design of the Kidney Precision Medicine Project. Kidney International, 2021, 99, 498-510.	5.2	94
9	Prospective Cohort Study of Renin-Angiotensin System Blocker Usage after Hospitalized Acute Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 26-36.	4.5	15
10	Integrating Patient Priorities with Science by Community Engagement in the Kidney Precision Medicine Project. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 660-668.	4.5	20
11	The Microbiome and p-Inulin in Hemodialysis: A Feasibility Study. Kidney360, 2021, 2, 445-455.	2.1	3
12	Multiphotonâ€Guided Creation of Complex Organâ€5pecific Microvasculature. Advanced Healthcare Materials, 2021, 10, e2100031.	7.6	34
13	Body mass index and chronic kidney disease outcomes after acute kidney injury: a prospective matched cohort study. BMC Nephrology, 2021, 22, 200.	1.8	3
14	Assessment of kidney proximal tubular secretion in critical illness. JCI Insight, 2021, 6, .	5.0	9
15	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. Kidney International, 2021, 100, 1101-1111.	5.2	13
16	Rescuing kidney patients from early demise: role of anti-cytokine therapies. Kidney International, 2021, 100, 1152-1154.	5.2	0
17	Achieved blood pressure post-acute kidney injury and risk of adverse outcomes after AKI: A prospective parallel cohort study. BMC Nephrology, 2021, 22, 270.	1.8	3
18	Arteriovenous Fistula Maturation, Functional Patency, and Intervention Rates. JAMA Surgery, 2021, 156, 1111	4.3	45

#	Article	IF	CITATIONS
19	Precision-porous polyurethane elastomers engineered for application in pro-healing vascular grafts: Synthesis, fabrication and detailed biocompatibility assessment. Biomaterials, 2021, 279, 121174.	11.4	21
20	Bridging the gap between in silico and in vivo by modeling opioid disposition in a kidney proximal tubule microphysiological system. Scientific Reports, 2021, 11, 21356.	3.3	16
21	Cross-validation of SARS-CoV-2 responses in kidney organoids and clinical populations. JCI Insight, 2021, 6, .	5.0	21
22	Differences in proximal tubular solute clearance across common etiologies of chronic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, 1916-1923.	0.7	8
23	Serum trace metal association with response to erythropoiesis stimulating agents in incident and prevalent hemodialysis patients. Scientific Reports, 2020, 10, 20202.	3.3	2
24	Supervised Exercise Intervention and Overall Activity in CKD. Kidney International Reports, 2020, 5, 1261-1270.	0.8	7
25	Genetic variation implicates plasma angiopoietin-2 in the development of acute kidney injury sub-phenotypes. BMC Nephrology, 2020, 21, 284.	1.8	18
26	Trajectory of Kidney Function: The Canary in Sepsis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1211-1212.	5.6	6
27	The current and future landscape of dialysis. Nature Reviews Nephrology, 2020, 16, 573-585.	9.6	252
28	Microphysiological system modeling of ochratoxin A-associated nephrotoxicity. Toxicology, 2020, 444, 152582.	4.2	23
29	Photoreactive Carboxybetaine Copolymers Impart Biocompatibility and Inhibit Plasticizer Leaching on Polyvinyl Chloride. ACS Applied Materials & Interfaces, 2020, 12, 41026-41037.	8.0	24
30	Modelling kidney disease using ontology: insights from the Kidney Precision Medicine Project. Nature Reviews Nephrology, 2020, 16, 686-696.	9.6	45
31	Profiling APOL1 Nephropathy Risk Variants in Genome-Edited Kidney Organoids with Single-Cell Transcriptomics. Kidney360, 2020, 1, 203-215.	2.1	18
32	The Authors Reply. Kidney International Reports, 2020, 5, 2405-2406.	0.8	0
33	Open microfluidic coculture reveals paracrine signaling from human kidney epithelial cells promotes kidney specificity of endothelial cells. American Journal of Physiology - Renal Physiology, 2020, 319, F41-F51.	2.7	8
34	Prevalence and Persistence of Uremic Symptoms in Incident Dialysis Patients. Kidney360, 2020, 1, 86-92.	2.1	21
35	Health Policy for Dialysis Care in Canada and the United States. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1669-1677.	4.5	6
36	Wearable artificial kidney: problems, progress and prospects. Nature Reviews Nephrology, 2020, 16, 558-559.	9.6	23

#	Article	IF	CITATIONS
37	An Improved Vascularized, Dual-Channel Microphysiological System Facilitates Modeling of Proximal Tubular Solute Secretion. ACS Pharmacology and Translational Science, 2020, 3, 496-508.	4.9	19
38	From local explanations to global understanding with explainable AI for trees. Nature Machine Intelligence, 2020, 2, 56-67.	16.0	2,869
39	Vascular access-specific health-related quality of life impacts among hemodialysis patients: qualitative development of the hemodialysis access-related quality of life (HARQ) instrument. BMC Nephrology, 2020, 21, 16.	1.8	9
40	Association of Tubular Solute Clearance with Symptom Burden in Incident Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 530-538.	4.5	4
41	Association Between Early Recovery of Kidney Function After Acute Kidney Injury and Long-term Clinical Outcomes. JAMA Network Open, 2020, 3, e202682.	5.9	77
42	Effects of diet and exercise on adipocytokine levels in patients with moderate to severe chronic kidney disease. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1375-1381.	2.6	10
43	Soluble ST2 and Galectin-3 and Progression of CKD. Kidney International Reports, 2019, 4, 103-111.	0.8	41
44	Impact of AKI on Urinary Protein Excretion: Analysis of Two Prospective Cohorts. Journal of the American Society of Nephrology: JASN, 2019, 30, 1271-1281.	6.1	28
45	Albuminuria, the High-Density Lipoprotein Proteome, and Coronary Artery Calcification in Type 1 Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1483-1491.	2.4	20
46	Integrated epigenomic profiling reveals endogenous retrovirus reactivation in renal cell carcinoma. EBioMedicine, 2019, 41, 427-442.	6.1	26
47	Translational Assessment of Drugâ€Induced Proximal Tubule Injury Using a Kidney Microphysiological System. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 316-325.	2.5	42
48	Integrated Functional Genomic Analysis Enables Annotation of Kidney Genome-Wide Association Study Loci. Journal of the American Society of Nephrology: JASN, 2019, 30, 421-441.	6.1	27
49	Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney International, 2019, 95, 973-982.	5.2	70
50	The association of glycated hemoglobin with mortality and ESKD among persons with diabetes and chronic kidney disease. Journal of Diabetes and Its Complications, 2019, 33, 296-301.	2.3	12
51	Identification of Acute Kidney Injury Subphenotypes with Differing Molecular Signatures and Responses to Vasopressin Therapy. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 863-872.	5.6	105
52	Kidneys on Chips. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 144-146.	4.5	14
53	Relationships Between Clinical Processes and Arteriovenous Fistula Cannulation and Maturation: AÂMulticenter Prospective Cohort Study. American Journal of Kidney Diseases, 2018, 71, 677-689.	1.9	59
54	Perioperative THR-184 and AKI after Cardiac Surgery. Journal of the American Society of Nephrology: JASN, 2018, 29, 670-679.	6.1	35

JONATHAN HIMMELFARB

#	Article	IF	CITATIONS
55	Weekly Standard Kt/Vurea and Clinical Outcomes in Home and In-Center Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 445-455.	4.5	16
56	Acute Kidney Injury and Risk of Incident Heart Failure Among US Veterans. American Journal of Kidney Diseases, 2018, 71, 236-245.	1.9	39
57	Comparison of the Complexity of Patients Seen by Different Medical Subspecialists in a Universal Health Care System. JAMA Network Open, 2018, 1, e184852.	5.9	181
58	Technology Transfer of the Microphysiological Systems: A Case Study of the Human Proximal Tubule Tissue Chip. Scientific Reports, 2018, 8, 14882.	3.3	58
59	Prediction of Arteriovenous Fistula Clinical Maturation from Postoperative Ultrasound Measurements: Findings from the Hemodialysis Fistula Maturation Study. Journal of the American Society of Nephrology: JASN, 2018, 29, 2735-2744.	6.1	103
60	Fabricating a Kidney Cortex Extracellular Matrix-Derived Hydrogel. Journal of Visualized Experiments, 2018, , .	0.3	9
61	Reconstructing the Human Renal Vascular–Tubular Unit In Vitro. Advanced Healthcare Materials, 2018, 7, 1801120.	7.6	44
62	High-Throughput Screening Enhances Kidney Organoid Differentiation from Human Pluripotent Stem Cells and Enables Automated Multidimensional Phenotyping. Cell Stem Cell, 2018, 22, 929-940.e4.	11.1	328
63	Human Organ-Specific Endothelial Cell Heterogeneity. IScience, 2018, 4, 20-35.	4.1	181
64	Effect of Anti-Hypertensive Medication History on Arteriovenous Fistula Maturation Outcomes. American Journal of Nephrology, 2018, 48, 56-64.	3.1	4
65	Novel PAradigm to improve Inflammatory burden in end stage Renal disease (rePAIR): study protocol for a randomized controlled trial. Trials, 2018, 19, 370.	1.6	3
66	A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia, 2018, 20, 610-620.	5.3	78
67	Bioelectrical Impedance Analysis Measures and Clinical Outcomes in CKD. American Journal of Kidney Diseases, 2018, 72, 662-672.	1.9	37
68	GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD. American Journal of Kidney Diseases, 2018, 72, 519-528.	1.9	82
69	Chronic kidney disease attenuates the plasma metabolome response to insulin. JCI Insight, 2018, 3, .	5.0	21
70	Human kidney on a chip assessment of polymyxin antibiotic nephrotoxicity. JCl Insight, 2018, 3, .	5.0	60
71	Reevaluating the role of megalin in renal vitamin D homeostasis using a human cell-derived microphysiological system. ALTEX: Alternatives To Animal Experimentation, 2018, 35, 504-515.	1.5	19
72	Growth Differentiation Factor–15 and Risk of CKD Progression. Journal of the American Society of Nephrology: JASN, 2017, 28, 2233-2240.	6.1	127

#	Article	IF	CITATIONS
73	Global Cardiovascular and Renal Outcomes of Reduced GFR. Journal of the American Society of Nephrology: JASN, 2017, 28, 2167-2179.	6.1	194
74	The CKD Classification System in the Precision Medicine Era. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 346-348.	4.5	32
75	Effect of Coenzyme Q10 on Biomarkers of Oxidative Stress andÂCardiac Function in Hemodialysis Patients: The CoQ10 Biomarker Trial. American Journal of Kidney Diseases, 2017, 69, 389-399.	1.9	48
76	Indication for Dialysis Initiation and Mortality in Patients With Chronic Kidney Failure: A Retrospective Cohort Study. American Journal of Kidney Diseases, 2017, 69, 41-50.	1.9	40
77	Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidneyÂdisease. Nature Materials, 2017, 16, 1112-1119.	27.5	225
78	Histopathology of Veins Obtained at Hemodialysis Arteriovenous Fistula Creation Surgery. Journal of the American Society of Nephrology: JASN, 2017, 28, 3076-3088.	6.1	39
79	Intimal Hyperplasia, Stenosis, and Arteriovenous Fistula Maturation Failure in the Hemodialysis Fistula Maturation Study. Journal of the American Society of Nephrology: JASN, 2017, 28, 3005-3013.	6.1	96
80	Kidney function is associated with an altered protein composition of high-density lipoprotein. Kidney International, 2017, 92, 1526-1535.	5.2	37
81	Clinical Genetic Testing for APOL1 : Are we There Yet?. Seminars in Nephrology, 2017, 37, 552-557.	1.6	29
82	Identification, Confirmation, and Replication of Novel Urinary MicroRNA Biomarkers in Lupus Nephritis and Diabetic Nephropathy. Clinical Chemistry, 2017, 63, 1515-1526.	3.2	76
83	Circulating levels of soluble Fas (sCD95) are associated with risk for development of a nonresolving acute kidney injury subphenotype. Critical Care, 2017, 21, 217.	5.8	17
84	Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity. JCI Insight, 2017, 2, .	5.0	124
85	A wearable artificial kidney for patients with end-stage renal disease. JCI Insight, 2016, 1, .	5.0	111
86	Storage Time and Urine Biomarker Levels in the ASSESS-AKI Study. PLoS ONE, 2016, 11, e0164832.	2.5	18
87	Association of markers of endothelial dysregulation Ang1 and Ang2 with acute kidney injury in critically ill patients. Critical Care, 2016, 20, 207.	5.8	36
88	Physical activity and metabolic health in chronic kidney disease: a cross-sectional study. BMC Nephrology, 2016, 17, 187.	1.8	20
89	Risk Factors for Rapid Kidney Function Decline Among African Americans: The Jackson Heart Study (JHS). American Journal of Kidney Diseases, 2016, 68, 229-239.	1.9	66
90	Decellularized Human Kidney Cortex Hydrogels Enhance Kidney Microvascular Endothelial Cell Maturation and Quiescence. Tissue Engineering - Part A, 2016, 22, 1140-1150.	3.1	68

Jonathan Himmelfarb

#	Article	IF	CITATIONS
91	Markers of kidney disease and risk of subclinical and clinical heart failure in African Americans: the Jackson Heart Study. Nephrology Dialysis Transplantation, 2016, 31, 2057-2064.	0.7	10
92	Development of a microphysiological model of human kidney proximal tubule function. Kidney International, 2016, 90, 627-637.	5.2	198
93	Extended-hours hemodialysis is associated withÂlower mortality risk in patients with end-stageÂrenal disease. Kidney International, 2016, 90, 1312-1320.	5.2	32
94	Abundance of Drug Transporters in the Human Kidney Cortex as Quantified by Quantitative Targeted Proteomics. Drug Metabolism and Disposition, 2016, 44, 1920-1924.	3.3	114
95	Diabetes, Kidney Disease, and Cardiovascular Outcomes in the Jackson Heart Study. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1384-1391.	4.5	32
96	Acute kidney injury subphenotypes based on creatinine trajectory identifies patients at increased risk of death. Critical Care, 2016, 20, 372.	5.8	58
97	Risk prediction to inform surveillance of chronic kidney disease in the US Healthcare Safety Net: a cohort study. BMC Nephrology, 2016, 17, 57.	1.8	7
98	Dietary Acid Load is Associated With Serum Bicarbonate but not Insulin Sensitivity in Chronic Kidney Disease. , 2016, 26, 93-102.		27
99	Racial and Ethnic Disparities in Use of and Outcomes with Home Dialysis in the United States. Journal of the American Society of Nephrology: JASN, 2016, 27, 2123-2134.	6.1	77
100	Tubular Secretion in CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 2148-2155.	6.1	83
101	A Novel Three–Dimensional Human Peritubular Microvascular System. Journal of the American Society of Nephrology: JASN, 2016, 27, 2370-2381.	6.1	77
102	Association of Vascular Access Type with Mortality, Hospitalization, and Transfer to In-Center Hemodialysis in Patients Undergoing Home Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 298-307.	4.5	31
103	Functional Comparison of Human Colonic Carcinoma Cell Lines and Primary Small Intestinal Epithelial Cells for Investigations of Intestinal Drug Permeability and First-Pass Metabolism. Drug Metabolism and Disposition, 2016, 44, 329-335.	3.3	47
104	A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. Journal of the American Society of Nephrology: JASN, 2016, 27, 1015-1028.	6.1	94
105	Rapid and sensitive analysis of reduced and oxidized coenzyme Q10 in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and application to studies in healthy human subjects. Annals of Clinical Biochemistry, 2016, 53, 265-273.	1.6	14
106	Association of FMO3 Variants and Trimethylamine N-Oxide Concentration, Disease Progression, and Mortality in CKD Patients. PLoS ONE, 2016, 11, e0161074.	2.5	48
107	Associations between single nucleotide polymorphisms in the FAS pathway and acute kidney injury. Critical Care, 2015, 19, 368.	5.8	10
108	Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress. BMC Nephrology, 2015, 16, 183.	1.8	49

Jonathan Himmelfarb

#	Article	IF	CITATIONS
109	A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects. Journal of Proteome Research, 2015, 14, 2792-2806.	3.7	46
110	Maintenance Dialysis throughout the World in Years 1990 and 2010. Journal of the American Society of Nephrology: JASN, 2015, 26, 2621-2633.	6.1	159
111	Predictors of treatment with dialysis modalities in observational studies for comparative effectiveness research. Nephrology Dialysis Transplantation, 2015, 30, 1208-1217.	0.7	48
112	Creatinine Clearance, Walking Speed, and Muscle Atrophy: AÂCohort Study. American Journal of Kidney Diseases, 2015, 65, 737-747.	1.9	51
113	Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients. BMC Nephrology, 2015, 16, 79.	1.8	9
114	Volume Overload: Prevalence, Risk Factors, and Functional Outcome in Survivors of Septic Shock. Annals of the American Thoracic Society, 2015, 12, 1837-1844.	3.2	89
115	Border Health. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1892-1894.	4.5	0
116	Changes in symptom burden and physical performance with initiation of dialysis in patients with chronic kidney disease. Hemodialysis International, 2015, 19, 147-150.	0.9	12
117	Urine matrix metalloproteinase-7 and risk of kidney disease progression and mortality in type 2 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 1024-1031.	2.3	22
118	A Pilot Randomized Crossover Trial Assessing the Safety and Short-Term Effects of Pomegranate Supplementation in Hemodialysis Patients. , 2015, 25, 40-49.		24
119	Self-Rated Health and Adverse Events in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 2044-2051.	4.5	28
120	Provision of Antioxidant Therapy in Hemodialysis (PATH). Journal of the American Society of Nephrology: JASN, 2014, 25, 623-633.	6.1	62
121	Acute Kidney Injury Is Associated with Increased Hospital Mortality after Stroke. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 25-30.	1.6	60
122	Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney International, 2014, 85, 522-528.	5.2	157
123	Objectives and Design of the Hemodialysis Fistula Maturation Study. American Journal of Kidney Diseases, 2014, 63, 104-112.	1.9	115
124	Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease. International Journal of Cardiology, 2014, 176, 99-109.	1.7	87
125	New Therapies for Diabetic Kidney Disease. New England Journal of Medicine, 2013, 369, 2549-2550.	27.0	75
126	Hemodialysis. New England Journal of Medicine, 2010, 363, 1833-1845.	27.0	267

8

#	Article	IF	CITATIONS
127	Innovation in the Treatment of Uremia: Proceedings from the Cleveland Clinic Workshop: Uremic Toxicity, Oxidative Stress, and Hemodialysis as Renal Replacement Therapy. Seminars in Dialysis, 2009, 22, 636-643.	1.3	104
128	Creating Research Infrastructure and Functionality to Address Chronic Kidney Disease: The Kidney Research Institute. Seminars in Nephrology, 2009, 29, 457-466.	1.6	1
129	Acute Kidney Injury in the Elderly: Problems and Prospects. Seminars in Nephrology, 2009, 29, 658-664.	1.6	35
130	Evaluation and Initial Management of Acute Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 962-967.	4.5	118
131	Oxidative Stress in Hemodialysis. , 2008, 161, 132-137.		50
132	Oxidative Stress and Inflammation Are Associated with Adiposity in Moderate to Severe CKD. Journal of the American Society of Nephrology: JASN, 2008, 19, 593-599.	6.1	180
133	End-Stage Renal Disease Measures of Quality. Annual Review of Medicine, 2007, 58, 387-399.	12.2	16
134	Continuous Renal Replacement Therapy in the Treatment of Acute Renal Failure: Critical Assessment Is Required. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 385-389.	4.5	21
135	Chronic Kidney Disease and the Public Health. JAMA - Journal of the American Medical Association, 2007, 297, 2630.	7.4	43
136	Cost, Quality, and Value. Journal of the American Society of Nephrology: JASN, 2007, 18, 2021-2027.	6.1	35
137	Iron Regulation. Journal of the American Society of Nephrology: JASN, 2007, 18, 379-381.	6.1	15
138	Gamma-Tocopherol and Docosahexaenoic Acid Decrease Inflammation in Dialysis Patients. , 2007, 17, 296-304.		91
139	Dialysis at a Crossroads: Reverse Engineering Renal Replacement Therapy. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 896-902.	4.5	9
140	Opinion: What is the Current and Future Status of Interventional Nephrology?. Seminars in Dialysis, 2005, 18, 375-377.	1.3	0
141	Hemodialysis Complications. American Journal of Kidney Diseases, 2005, 45, 1122-1131.	1.9	51
142	Relevance of Oxidative Pathways in the Pathophysiology of Chronic Kidney Disease. Cardiology Clinics, 2005, 23, 319-330.	2.2	63
143	Oxidative Stress Is Increased in Critically III Patients with Acute Renal Failure. Journal of the American Society of Nephrology: JASN, 2004, 15, 2449-2456.	6.1	219
144	Payment for Quality in End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2004. 15. 3263-3269.	6.1	21

JONATHAN HIMMELFARB

#	Article	IF	CITATIONS
145	Impaired monocyte cytokine production in critically ill patients with acute renal failure. Kidney International, 2004, 66, 2354-2360.	5.2	51
146	POOR NUTRITIONAL STATUS AND INFLAMMATION: Linking Oxidative Stress and Inflammation in Kidney Disease: Which is the Chicken and Which is the Egg?. Seminars in Dialysis, 2004, 17, 449-454.	1.3	117
147	Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney International, 2003, 64, 978-991.	5.2	98
148	Oxidative stress in uremia. Current Opinion in Nephrology and Hypertension, 2003, 12, 593-598.	2.0	148
149	The HEMO study - where do we go from here?. Current Opinion in Nephrology and Hypertension, 2003, 12, 587-591.	2.0	7
150	Urea volume of distribution exceeds total body water in patients with acute renal failure. Kidney International, 2002, 61, 317-323.	5.2	66
151	The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney International, 2002, 62, 1524-1538.	5.2	1,012
152	Quantitating Urea Removal in Patients with Acute Renal Failure: Lost Art or Forgotten Science?. Seminars in Dialysis, 2001, 13, 147-149.	1.3	15
153	Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radical Biology and Medicine, 2001, 31, 1163-1169.	2.9	110
154	The Importance of Biocompatible Membranes in Dialysis. Seminars in Dialysis, 1996, 9, 481-483.	1.3	5
155	Dialytic Therapy in Acute Renal Failure: No Reason for Nihilism. Seminars in Dialysis, 1996, 9, 230-234.	1.3	4